The potential emerging pharmacological treatments for metabolic syndrome, especially for obesity and DM with glucagon-like peptide-1 receptor agonists (GLP1A), might promise a secure way for prevention of bone formation in this context, a hypothesis that should be further explored [26]. This evidence concerns the gene GLP1R and metabolic syndrome.